CSIMarket Company Name, Ticker, Competitors, else..
 
Vtv Therapeutics Inc   (NASDAQ: VTVT)
 
Price: $32.0000 $-0.36 -1.112%
Day's High: $32.21500015258789 Week Perf: -5.63 %
Day's Low: $ 31.35 30 Day Perf: -1.08 %
Volume (M): 94,151 52 Wk High: $ 44.00
Volume (M$): $ 0 52 Wk Avg: $31.80
Open: $31.88 52 Wk Low: $17.00



 Market Capitalization (Millions $) 468
 Shares Outstanding (Millions) 15
 Employees 26
 Revenues (TTM) (Millions $) 37
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 67
 Capital Exp. (TTM) (Millions $) 0

Business Description


Vtv Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative small molecule drugs to treat various diseases. The company is known for its expertise in target-based drug discovery and employs a unique approach to drug development, utilizing cutting-edge technologies and collaborative research partnerships. Vtv Therapeutics aims to bring novel therapeutics to the market that can significantly improve patient outcomes and address unmet medical needs.


   Company Address: 3980 Premier Dr High Point 27265 NC
   Company Phone Number: 841-0300   Stock Exchange / Ticker: NASDAQ VTVT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -0.7%    
EBS        17.76% 
ONC   -3.33%    
REGN   -3.55%    
TEVA   -2.38%    
VTRS   -0.18%    
• View Complete Report
   



Clinical Study

Breaking Barriers in Diabetes Treatment A Corporate and Clinical Progress Report from vTv Therapeutics

Published Fri, Mar 21 2025 7:47 PM UTC

: vTv Therapeutics, a clinical-stage pharmaceutical company, has released its financial results for the fourth quarter and full year of 2024. The announcement highlights strategic corporate advancements alongside significant clinical developments, including the lifting of a clinical hold for their late-stage cadisegliatin program for diabetes. This article examines the imp...
Clinical Study

FDA Places Clinical Hold on vTv Therapeutics Cadisegliatin Program for Type 1 Diabetes

Published Fri, Jul 26 2024 8:05 PM UTC

vTv Therapeutics Inc. Faces Setback in Promising Diabetes Research HIGH POINT, N.C., July 26, 2024 vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company renowned for its innovative clinical portfolio of small molecules and a lead program targeting diabetes, today announced a significant development. The United States Food and Drug Administration (FDA...
Product Service News

vTv Therapeutics Takes a Major Step Towards the Treatment of Type 1 Diabetes with Cadisegliatin as FDA Receives Phase 3 Study Protocol Submission

Published Mon, Mar 4 2024 1:01 PM UTC




vTv Therapeutics Inc., a renowned clinical stage biopharmaceutical company with a focus on the development of innovative treatments, has recently submitted the study protocol for its first Phase 3 trial to the U.S. Food and Drug Administration (FDA). This trial aims to evaluate the safety and efficacy of their lead candidate, cadisegliatin (TTP399), as an adj...
Financing Agreement

vTv Therapeutics Secures $51 Million Funding to Advance Cadisegliatin and Tackle Type 1 Diabetes

Published Wed, Feb 28 2024 1:00 PM UTC



vTv Therapeutics, a renowned pharmaceutical company focused on developing innovative treatments for chronic diseases, has recently announced a major milestone in its journey to combat type 1 diabetes (T1D). The company has successfully raised $51 million through a private placement from prominent healthcare-focused institutional investors and the JDRF T1D Fund.



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 12.71
Price to Sales (Expected) -
Price to Book 5.21
PEG (TTM) -

Financial Strength Current
Quick Ratio 14.25
Working Capital Ratio 14.36
Leverage Ratio (MRQ) 0.1
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.82 $
Revenues (TTM) 2.52 $
Cash Flow (TTM) 4.58 $
Cash 6.7 $
Book Value 6.15 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,416,885
Net Income per Employee (TTM) -28,038
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.47

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) 63.15 %
Net Margin (MRQ) 65.51 %
Net Cash Flow Margin (MRQ) 24.85 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Vtv Therapeutics Inc's Segments
Reportable Segment    99.89 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.